Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

Condition:   Squamous Cell Carcinoma of the Head and Neck Interventions:   Drug: Monalizumab;   Drug: Cetuximab Sponsors:   AstraZeneca;   Innate Pharma Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials